Chwilio Deddfwriaeth

Chwiliad Uwch

Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC)

Help about what version

Pa Fersiwn

Help about UK-EU Regulation

Legislation originating from the EU

When the UK left the EU, legislation.gov.uk published EU legislation that had been published by the EU up to IP completion day (31 December 2020 11.00 p.m.). On legislation.gov.uk, these items of legislation are kept up-to-date with any amendments made by the UK since then.

Close

Mae hon yn eitem o ddeddfwriaeth sy’n deillio o’r UE

Mae unrhyw newidiadau sydd wedi cael eu gwneud yn barod gan y tîm yn ymddangos yn y cynnwys a chyfeirir atynt gydag anodiadau.Ar ôl y diwrnod ymadael bydd tair fersiwn o’r ddeddfwriaeth yma i’w gwirio at ddibenion gwahanol. Y fersiwn legislation.gov.uk yw’r fersiwn sy’n weithredol yn y Deyrnas Unedig. Y Fersiwn UE sydd ar EUR-lex ar hyn o bryd yw’r fersiwn sy’n weithredol yn yr UE h.y. efallai y bydd arnoch angen y fersiwn hon os byddwch yn gweithredu busnes yn yr UE. EUR-Lex Y fersiwn yn yr archif ar y we yw’r fersiwn swyddogol o’r ddeddfwriaeth fel yr oedd ar y diwrnod ymadael cyn cael ei chyhoeddi ar legislation.gov.uk ac unrhyw newidiadau ac effeithiau a weithredwyd yn y Deyrnas Unedig wedyn. Mae’r archif ar y we hefyd yn cynnwys cyfraith achos a ffurfiau mewn ieithoedd eraill o EUR-Lex. The EU Exit Web Archive legislation_originated_from_EU_p3

Changes to legislation:

Commission Decision of 7 May 2002 on common technical specifications for in vitro-diagnostic medical devices (notified under document number C(2002) 1344) (Text with EEA relevance) (2002/364/EC) is up to date with all changes known to be in force on or before 17 August 2024. There are changes that may be brought into force at a future date. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. Changes and effects are recorded by our editorial team in lists which can be found in the ‘Changes to Legislation’ area. Where those effects have yet to be applied to the text of the legislation by the editorial team they are also listed alongside the affected provisions when you open the content using the Table of Contents below.

View outstanding changes

Changes and effects yet to be applied to :

  • Annex Point 2 Text addition by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.4.2 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 2 Text replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Table 3 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.11 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.1 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Table 4 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.3 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Table 1 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Annex Point 3 Point 3.1.9 replacement by EUDN 2020/350 Decision (This amendment by the EU not applied to legislation.gov.uk because it is brought into force after IP completion day.)
  • Decision revoked by S.I. 2002/618, reg. 4H(1) (as inserted) by S.I. 2019/791 reg. 3(7)
  • Annex point 3.1.4 words substituted by S.I. 2021/873 Sch. 2 para. 3(a)(ii) (This amendment not applied to legislation.gov.uk. The words 'CE marked' do not appear in 3.1.4 following its substitution by Commission Decision of 27 November 2009 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (2009/886/EC))
  • Annex point 3.4.1 words substituted by S.I. 2021/873 Sch. 2 para. 3(c)(i) (This amendment not applied to legislation.gov.uk. The words 'CE marking' do not appear in 3.4.1 following its substitution by Commission Decision of 27 November 2009 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (2009/886/EC))
  • Annex point 3.4.1 words substituted by S.I. 2021/873 Sch. 2 para. 3(c)(ii) (This amendment not applied to legislation.gov.uk. The words 'CE marked' do not appear in 3.4.1 following its substitution by Commission Decision of 27 November 2009 amending Decision 2002/364/EC on common technical specifications for in vitro diagnostic medical devices (2009/886/EC))

  1. Introductory Text

  2. Article 1.The technical specifications set out in the Annex to this...

  3. Article 2.This Decision is addressed to the Member States.

    1. ANNEX

      COMMON TECHNICAL SPECIFICATIONS (CTS) FOR IN VITRO DIAGNOSTIC MEDICAL DEVICES

      1. 1. SCOPE

      2. 2. DEFINITIONS AND TERMS

        1. (Diagnostic) sensitivity

        2. True positive

        3. False negative

        4. (Diagnostic) specificity

        5. False positive

        6. True negative

        7. Analytical sensitivity

        8. Analytical specificity

        9. Nucleic acid amplification techniques (NAT)

        10. Rapid test

        11. Robustness

        12. Whole system failure rate

        13. Confirmation assay

        14. Virus typing assay

        15. Sero-conversion HIV samples

        16. Early sero-conversion HIV samples

      3. 3. COMMON TECHNICAL SPECIFICATIONS (CTS) FOR PRODUCTS REFERRED TO IN ANNEX...

        1. 3.1. CTS for performance evaluation of reagents and reagent products for...

          1. General principles

            1. 3.1.1. Devices which detect virus infections shall meet the requirements for...

            2. 3.1.2. Devices intended by the manufacturer for testing body fluids other...

            3. 3.1.3. Devices intended by the manufacturer for self-test, i.e. home use,...

            4. 3.1.4. All performance evaluations shall be carried out in direct comparison...

            5. 3.1.5. If discrepant test results are identified as part of an...

            6. 3.1.6. Performance evaluations shall be performed on a population equivalent to...

            7. 3.1.7. Positive specimens used in the performance evaluation shall be selected...

            8. 3.1.8. Sensitivity with true positives and sero-conversion samples shall be evaluated...

            9. 3.1.9. Performance evaluation of screening assays shall include 25 positive (if...

            10. 3.1.10. Negative specimens used in a performance evaluation shall be defined...

            11. 3.1.11. For performance evaluations for screening assays (Table 1) blood donor...

            12. 3.1.12. Devices shall have a specificity of at least 99,5 % on...

            13. 3.1.13. Devices shall be evaluated to establish the effect of potential...

            14. 3.1.14. For devices intended by the manufacturer to be used with...

            15. 3.1.15. For devices intended for use with plasma the performance evaluation...

            16. 3.1.16. As part of the required risk analysis the whole system...

            17. 3.1.17. If a new in vitro diagnostic medical device belonging to...

        2. 3.2. Additional requirements for HIV and HCV antigen and antibody combined...

          1. 3.2.1. HIV antigen and antibody combined tests intended for the detection...

          2. 3.2.2. Hepatitis C virus (HCV) antigen and antibody combined tests intended...

        3. 3.3. Additional requirements for nucleic acid amplification techniques (NAT)

          1. 3.3.1. For target sequence amplification assays, a functionality control for each...

          2. 3.3.2. The analytical sensitivity or detection limit for NAT assays shall...

          3. 3.3.2a. Qualitative HIV NAT assays intended to be used to detect...

          4. 3.3.2b. Qualitative HIV NAT assays, other than virus typing assays, shall...

          5. 3.3.3. Genotype detection shall be demonstrated by appropriate primer or probe...

          6. 3.3.4. Results of quantitative NAT assays shall be traceable to international...

          7. 3.3.5. NAT assays may be used to detect virus in antibody...

          8. 3.3.6. For investigation of potential carry-over, at least five runs with...

          9. 3.3.7. The whole system failure rate leading to false-negative results shall...

        4. 3.4. CTS for the manufacturer’s release testing of reagents and reagent...

          1. 3.4.1. The manufacturer’s release testing criteria shall ensure that every batch...

          2. 3.4.2. The manufacturer’s batch release testing for screening assays shall include...

        5. 3.5. CTS for performance evaluation of reagents and reagent products for...

          1. 3.5.1. All performance evaluations shall be carried out in direct comparison...

          2. 3.5.2. If discrepant test results are identified as part of an...

          3. 3.5.3. Performance evaluations shall be performed on a population equivalent to...

          4. 3.5.4. Positive specimens used in the performance evaluation shall be selected...

          5. 3.5.5. Devices shall be evaluated to establish the effect of potential...

          6. 3.5.6. For devices intended for use with plasma the performance evaluation...

        6. 3.6. CTS for the manufacturer’s release testing of reagents and reagent...

          1. 3.6.1. The manufacturer’s release testing criteria shall ensure that every batch...

          2. 3.6.2. Requirements for manufacturers batch release testing are outlined in Table...

        7. 3.7. CTS for Variant Creutzfeldt-Jakob disease (vCJD) assays for blood screening...

        8. Acceptance criteria:

        9. Qualifications:

        10. Table 10 Batch release criteria for reagents and reagent products to determine...Specificity testing requirements on each reagent 1. Test reagents Only...

          1. 1. Test reagents

            1. Acceptance criteria:

          2. 2. Control materials (red cells)

Yn ôl i’r brig

Options/Help

Print Options

Close

Mae deddfwriaeth ar gael mewn fersiynau gwahanol:

Y Diweddaraf sydd Ar Gael (diwygiedig):Y fersiwn ddiweddaraf sydd ar gael o’r ddeddfwriaeth yn cynnwys newidiadau a wnaed gan ddeddfwriaeth ddilynol ac wedi eu gweithredu gan ein tîm golygyddol. Gellir gweld y newidiadau nad ydym wedi eu gweithredu i’r testun eto yn yr ardal ‘Newidiadau i Ddeddfwriaeth’.

Gwreiddiol (Fel y’i mabwysiadwyd gan yr UE): Mae'r wreiddiol version of the legislation as it stood when it was first adopted in the EU. No changes have been applied to the text.

Close

Dewisiadau Agor

Dewisiadau gwahanol i agor deddfwriaeth er mwyn gweld rhagor o gynnwys ar y sgrin ar yr un pryd

Close

Rhagor o Adnoddau

Gallwch wneud defnydd o ddogfennau atodol hanfodol a gwybodaeth ar gyfer yr eitem ddeddfwriaeth o’r tab hwn. Yn ddibynnol ar yr eitem ddeddfwriaeth sydd i’w gweld, gallai hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted version that was used for the EU Official Journal
  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • pob fformat o’r holl ddogfennau cysylltiedig
  • slipiau cywiro
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill
Close

Llinell Amser Newidiadau

Mae’r llinell amser yma yn dangos y fersiynau gwahanol a gymerwyd o EUR-Lex yn ogystal ag unrhyw fersiynau dilynol a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig.

Cymerir dyddiadau fersiynau’r UE o ddyddiadau’r dogfennau ar EUR-Lex ac efallai na fyddant yn cyfateb â’r adeg pan ddaeth y newidiadau i rym ar gyfer y ddogfen.

Ar gyfer unrhyw fersiynau a grëwyd ar ôl y diwrnod ymadael o ganlyniad i newidiadau a wnaed gan ddeddfwriaeth y Deyrnas Unedig, bydd y dyddiad yn cyd-fynd â’r dyddiad cynharaf y daeth y newid (e.e. ychwanegiad, diddymiad neu gyfnewidiad) a weithredwyd i rym. Am ragor o wybodaeth gweler ein canllaw i ddeddfwriaeth ddiwygiedig ar Ddeall Deddfwriaeth.

Close

Rhagor o Adnoddau

Defnyddiwch y ddewislen hon i agor dogfennau hanfodol sy’n cyd-fynd â’r ddeddfwriaeth a gwybodaeth am yr eitem hon o ddeddfwriaeth. Gan ddibynnu ar yr eitem o ddeddfwriaeth sy’n cael ei gweld gall hyn gynnwys:

  • y PDF print gwreiddiol y fel adopted fersiwn a ddefnyddiwyd am y copi print
  • slipiau cywiro

liciwch ‘Gweld Mwy’ neu ddewis ‘Rhagor o Adnoddau’ am wybodaeth ychwanegol gan gynnwys

  • rhestr o newidiadau a wnaed gan a/neu yn effeithio ar yr eitem hon o ddeddfwriaeth
  • manylion rhoi grym a newid cyffredinol
  • pob fformat o’r holl ddogfennau cysylltiedig
  • dolenni i ddeddfwriaeth gysylltiedig ac adnoddau gwybodaeth eraill